Al Ghorani, Hussam http://orcid.org/0000-0003-0142-4908
Kulenthiran, Saarraaken
Lauder, Lucas http://orcid.org/0000-0003-1434-9556
Recktenwald, Michael Johannes Maria
Dederer, Juliane
Kunz, Michael
Götzinger, Felix
Ewen, Sebastian
Ukena, Christian
Böhm, Michael
Mahfoud, Felix http://orcid.org/0000-0002-4425-549X
Funding for this research was provided by:
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Article History
Received: 21 December 2023
Accepted: 16 February 2024
First Online: 7 March 2024
Declarations
:
: HA, MJMR and MK do not have COI to declare. SK has received speaker honoraria from Medtronic and ReCor. LL has received speaker honoraria from AstraZeneca, Medtronic, Pfizer and ReCor. FG received speaker honoraria from AstraZeneca and is supported by the German Foundation for Heart Research/Deutsche Herzstiftung. SE received speaker honoraria and/or travel support from Akcea Therapeutics, AstraZeneca, Bayer, Berlin Chemie, Bristol-Myers Squibb—Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Kaneka Pharma, Medtronic, Novartis and ReCor. CU received scientific support and speaker honoraria from Bayer, Boehringer Ingelheim, Medtronic, Pfizer and ReCor. MB is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TRR 219, Project-ID 322900939) and reports personal fees from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Servier, Medtronic, Vifor, Novartis and Abbott. FM is supported by Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939), and Deutsche Herzstiftung, received scientific support from Ablative Solutions, Medtronic and Recor. He has received speaker honoraria/consulting fees from his institution (Saarland University), Ablative Solutions, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, ReCor, Servier, and Terumo.
: We have previously published results of the change in 24-h blood pressure (BP) and renal functions over time as well as limited safety data in a research letter in JACC under the title '10-Year Outcomes of Catheter-Based Renal Denervation in Patients With Resistant Hypertension' (JACC VOL. 81, NO.5, 2023, ISSN 0735-1097). Herein, we present the full data set including different BP measurement methods, BP control rates, utilization of antihypertensive drugs, and changes in renal resistance indices, which are important to assess the efficacy and safety of renal denervation in the long term. The present manuscript therefore differs significantly from the research letter not only regarding the type but also the content of the manuscript, which is novel.